TDM Helps Ensure the Proper Administration of Cibenzoline

DOI NDL Digital Collections 8 References
  • Fukumoto Kyoko
    Department of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences
  • Yoshioka Rie
    Department of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences
  • Tsuchishita Yosimasa
    Department of Pharmacy, Maizuru Kyosai Hospital Federation of National Public Services and Affiliated Mutual Association
  • Kobayashi Junjiro
    Department of Cardiovascular Surgery, National Cardiovascular Center
  • Kamakura Shiro
    Department of Cardiovascular Internal Medicine, National Cardiovascular Center
  • Ueno Kazuyuki
    Department of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences

Bibliographic Information

Other Title
  • シベンゾリンの適正投与に対するＴＤＭの寄与

Search this article

Abstract

Owing to their narrow therapeutic range, most antiarrhythmic agents require Therapeutic Drug Monitoring (TDM). Though TDM is an effective tool for adjusting the individual dosage to the optimum level, no study has shown that TDM is useful for dose adjustment in the case of cibenzoline. The aim of this study was thus to evaluate the usefulness of TDM in cibenzoline therapy.<BR>In the National Cardiovascular Center, TDM was introduced for cibenzoline in 1998. This resulted in reductions in mean serum concentrations and mean doses, and very few adverse effects have been reported. Thanks to dosage adjustment based on TDM, there was a decrease in the proportion of patients having serum concentrations of above 400 ng/mL from 2000 onwards. These results suggest that TDM is an effective tool for preventing cibenzoline toxicity and that it helps to ensure that cibenzoline is administered properly.

Journal

References(8)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top